Vertex Pharmaceuticals
NasdaqGS:VRTX Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 210 Fair Values set on narratives written by author
WA
Consensus Narrative from 30 Analysts
Advancements Like VX-880 Will Transform Future Of Rare Disease Treatments
Key Takeaways Expanding patient access and new product launches drive revenue growth in cystic fibrosis and highlight significant revenue potential. Advancements in transformative therapies like VX-880 and global expansions offer substantial opportunities for revenue diversification and growth.
View narrativeUS$489.21
FV
1.0% undervalued intrinsic discount8.38%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
30users have followed this narrative
24 days ago author updated this narrative